Cost-Efficient Long-Read Trio-Barcoded Adaptive Sequencing Improves Rare Disease Diagnosis
核心洞察
A cost-efficient long-read sequencing approach using trio-barcoded adaptive sampling improves diagnostic yield in rare disease (搜索) cases.
The method integrates genomic analysis through targeted long-read sequencing with adaptive sampling, reducing sequencing costs while maintaining accuracy.
Trio-barcoding enables simultaneous analysis of patient and parental samples, enhancing variant phasing and interpretation for rare disease (搜索) diagnosis.
A newly described sequencing strategy combines long-read technology with trio-barcoded adaptive sampling to improve the diagnosis of rare diseases while reducing costs. The approach, detailed in research published in Nature Communications, addresses a persistent challenge in clinical genomics: achieving comprehensive, high-resolution genomic analysis without the prohibitive expense that has historically limited the widespread adoption of long-read sequencing in diagnostic settings.
The method leverages adaptive sampling, a technique that selectively enriches regions of interest during sequencing, paired with trio-barcoding that allows patient and parental samples to be processed and analyzed together. This integrated design enables the simultaneous capture of genomic information across a family trio, facilitating more accurate variant phasing and interpretation than would be possible with individual sample analysis alone.
A key advantage highlighted in the source material is cost efficiency. By focusing sequencing capacity on clinically relevant genomic regions through adaptive sampling, the approach reduces the overall sequencing burden while preserving the resolution needed to detect structural variants and other complex genomic alterations that short-read methods may miss. This balance between cost and diagnostic power is particularly relevant for rare disease (搜索) cases, where identifying a causative variant can end a lengthy and expensive diagnostic odyssey.
The research is published under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format with appropriate credit to the original authors. This open-access framework supports broader dissemination and application of the method across the clinical genomics community.
A related study, published in Scientific Reports, describes targeted long-read sequencing with adaptive sampling to enable integrated genomic analysis. That work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, permitting non-commercial use, sharing, distribution, and reproduction, while restricting the sharing of adapted material derived from the article.
Together, these developments underscore a growing momentum toward making long-read sequencing a practical and economically viable tool for rare disease (搜索) diagnostics. By integrating adaptive sampling with family-based barcoding strategies, researchers are working to lower the barriers that have kept high-resolution genomic analysis out of routine clinical practice, with the ultimate goal of improving diagnostic outcomes for patients with rare and undiagnosed conditions.